Efficacy and safety of flumatinib in adults with Ph-positive ALL: a prospective observational study
Flumatinib combined with chemotherapy induced high remission rates and deep molecular responses in newly diagnosed Ph+ ALL patients, with a favorable safety profile. However, patients with CML-LBP or high-risk Ph+ ALL had poor treatment responses and outcomes, indicating the need for more aggressive intervention strategies in this high-risk population.
Authors
- Luoming Hua
- Jia Liu (ORCID: https://orcid.org/0000-0002-2845-1028)
- Jiangbo Zhang (ORCID: https://orcid.org/0000-0002-2027-0134)
- Jing Wang (ORCID: https://orcid.org/0000-0001-9981-5530)
- Huimei Guo
- Xue Hua (ORCID: https://orcid.org/0009-0007-7625-4049)
- Jianmei Xu (ORCID: https://orcid.org/0009-0007-7912-7328)
- Songying Zhao
Institutions
- Affiliated Hospital of Hebei University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fonc.2025.1721146
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00